Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma.

Explore this paper's citation graph

Summary

There is no firm evidence to support or refute TACE or TAE for patients with unresectable HCC, indicating the need for future randomisation of up to 383 additional participants.

Type
review
Published
2011-03-16
Cited by
276
References
96
Access
Open access

Keywords

Medicine, Meta-analysis, Hazard ratio, Clinical trial, Randomized controlled trial

References

Cited by

Related papers